This company has been marked as potentially delisted and may not be actively trading. Pandion Therapeutics (PAND) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient TherapeuticsApril 29, 2025 | finance.yahoo.comSionna Therapeutics Announces the Appointment of Dr. Marcella Kuhlman Ruddy and Dr. Jo Viney to its Board of DirectorsJanuary 8, 2025 | finance.yahoo.comSEC settles insider trading case tied to theft from law firm CovingtonSeptember 18, 2024 | reuters.comLawsuits News | Today's Latest Stories | ReutersSeptember 17, 2024 | reuters.comPandion Therapeutics, Inc.September 10, 2024 | reuters.comSEC widens insider-trading case involving stolen law firm M&A infoSeptember 10, 2024 | reuters.comImmunomodulators Market Size to Worth USD 155.66 Billion by 2033August 27, 2024 | finance.yahoo.comMerck (MRK) Q1 2024 Earnings Call TranscriptApril 25, 2024 | finance.yahoo.comEx-FBI Trainee Gets 15 Months for Trading on Girlfriend’s InfoMarch 13, 2024 | bloomberg.comMallinckrodt plc: Mallinckrodt Announces Board of Directors and Leadership UpdatesFebruary 2, 2024 | finanznachrichten.deVC funding update: Which Boston-area startups raised money in December?January 4, 2024 | bizjournals.comFormer Pandion exec's new startup launches with $213M for gene-editingDecember 12, 2023 | bizjournals.comBiogen vet's new startup raises nine-figure round, moves to WatertownDecember 4, 2023 | bizjournals.comAptevo Therapeutics Inc APVONovember 1, 2023 | morningstar.comFormer Fox Chase Cancer Center leader and current Wistar CEO target $10M for new ventureSeptember 19, 2023 | bizjournals.comSarepta Therapeutics FDA Panel Live BlogJune 10, 2023 | thestreet.comAgile Therapeutics Stock (NASDAQ:AGRX), Quotes and News SummaryJanuary 11, 2023 | benzinga.comGet to know the BostInno Fire Awards life sciences honoreesNovember 22, 2022 | bizjournals.comCybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR SymposiumNovember 21, 2022 | finance.yahoo.comTour the latest co-laboratory space in LabCentral's networkOctober 24, 2022 | bizjournals.comJo Viney aims to be 'proactive and decisive' in allocating her timeOctober 5, 2022 | bizjournals.comOptimus Healthcare Services, Inc. Appoints John P. Sganga Chair of the Board of Directors and Chief Executive Officer of OptimusSeptember 20, 2022 | stockhouse.comSelecta Biosciences: A Derivative Play On Gene Therapies Via ImmTOR PlatformAugust 21, 2022 | seekingalpha.comSonoma Biotherapeutics Expands Board of Directors with Appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPHAugust 17, 2022 | finance.yahoo.comEx-Goldman banker tipped squash buddy on deals, US allegesJuly 25, 2022 | afr.comEx-U.S.congressman among 9 accused of insider tradingJuly 25, 2022 | msn.comSEC charges 10 people with insider trading in four cases (update)July 25, 2022 | seekingalpha.comFormer congressman among nine charged with insider tradingJuly 25, 2022 | msn.comProsecutors say FBI trainee stole tips from lawyer-girlfriend to trade on Merck dealJuly 25, 2022 | reuters.comEx-Congressman Stephen Buyer, FBI trainee indicted for insider tradingJuly 25, 2022 | nypost.comInvestment banker, ex-FBI trainee charged with insider tradingJuly 25, 2022 | msn.comMerck to hire another 100 at newly expanded Cambridge research labMay 25, 2022 | bizjournals.comVentus Therapeutics Appoints Stuart Green, M.D., as Chief Medical OfficerMay 2, 2022 | finance.yahoo.comThese 3 Dow Stocks Are Set to Soar in 2022's Second Half and BeyondApril 25, 2022 | msn.comStartup tackling autoimmune disease launches with $101M in venture capital fundingFebruary 9, 2022 | bizjournals.comPandion Therapeutics Holdco Llc (PAND)January 5, 2022 | investing.comMission BioCapital Boosts Team to Support Investments From New FundDecember 8, 2021 | finance.yahoo.comModerna millionaires and the double-edged sword of stock market richesNovember 7, 2021 | msn.comModerna millionaires and the doubled-edged sword of stock market richesNovember 6, 2021 | msn.comDeparted Moderna chief medical officer jumps to OrbiMedNovember 1, 2021 | bizjournals.comMarché Health Launches Digital Health Marketplace and Community with 350 Vetted Solutions to StartOctober 5, 2021 | finance.yahoo.comFour firms shape Merck’s $11.5 bln bet on drugmaker AcceleronSeptember 30, 2021 | reuters.comMerck weighed down by charges in Q2, but drug sales reboundJuly 29, 2021 | sfgate.comMerck Announces Second-Quarter 2021 Financial ResultsJuly 29, 2021 | benzinga.comMerck stock slips after adjusted profit matches expectations, while revenue beatsJuly 29, 2021 | morningstar.com Get Pandion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PAND and its competitors with MarketBeat's FREE daily newsletter. Email Address PAND Media Mentions By Week PAND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PAND News Sentiment▼0.000.73▲Average Medical News Sentiment PAND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PAND Articles This Week▼10▲PAND Articles Average Week Get Pandion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PAND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies JAZZ News Today TGTX News Today BBIO News Today LEGN News Today VRNA News Today SRPT News Today TLX News Today BPMC News Today NUVL News Today AXSM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PAND) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pandion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pandion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PAND Stock Free PAND Stock Alerts